Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?

Table 6 Major studies tested the efficacy of first generation direct antiviral agents combined with peg-interferon and ribavirin in liver transplant recipients

Ref.	Year of publication	No. of patients	Sustained virological response
Coilly et al[73]	2013	37	50% (20% for telaprevir and 71% for boceprevir)
Pungpapong et al[74]	2013	60	56% (67% for telaprevir and 45% for boceprevir)
Werner et al[75]	2012	9	89%
Stravitz et al[76]	2013	122	28%
Ann Brown et al[77]	2013	46	60%
Faisal et al[78]	2014	76	59.5%
Werner et al[79]	2014	14	50%